Document is current
Any future updates will be listed below
-
Authors
Weinmann-Menke, Julia
Wendtner, Clemens-Martin
Häckl, Dennis
Lohe, Vanessa
Dang, Phi Long
Jah, Fungwe
Kneidinger, Nikolaus
-
Funding
Funding for this research was provided by:
AstraZeneca GmbH Germany
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 17 March 2025
First Online: 11 April 2025
Declarations
:
: J.W-M., C-M.W., D.H. and N.K. received consulting fees for preparing the manuscript from AstraZeneca GmbH Germany. D.H. is an employee of WIG2 GmbH. The WIG2 GmbH is a contractor of AstraZeneca GmbH. P.L.D., V.L., and F. J. are employees of AstraZeneca GmbH. F.J. owns shares of CureVac. C-M.W. has received honoraria, travel, and research support from AstraZeneca GmbH, F. Hoffmann-La Roche AG, Janssen-Cilag GmbH, AbbVie Inc. and BeiGene Ltd. J.W.-M. participates as a Principal Investigator in the SUPERNOVA study (funded by AstraZeneca GmbH), is spokeswoman for the German Association of Nephrology and member of AWMF.
